The US company, Moderna Pharmaceutical Industries, has announced that the clinical trials of its vaccine against the Covid-19 pandemic will enter the final stage on July 27, making it the first company to reach this advanced stage.

And data showed the preliminary experiments of the vaccine developed by Moderna against Covid-19, that it is safe and stimulates an immune response, in a move considered a precedent for the American company facing strong competition from dozens of international companies.

When reviewing the results, our medical director, Dr. Tal Zacks, said it was a "good day for us" and added that "although the preventive effect of the vaccine is not technically known yet, all indications are that mRNA-1273 will be Safe and effective. "

And US media quoted Zachs as saying that the levels of antibody produced by the participants in the experiment were similar to those in patients who recovered from Covid-19, indicating that the candidate vaccine provided the same protection.

In addition, the upcoming vaccine did not generate a type of immune cell that made people with other diseases, when vaccinated, worse off, according to Zaks.

In this third and final stage, clinical trials will be conducted on 30,000 people in the United States, half of whom will receive doses of 100 micrograms of the vaccine, while the other half will receive a placebo. Researchers will follow up on these people for two years to see if the vaccine is safe and effective in preventing SARS-2 infection.

Also, in the case of people who can develop the disease despite being vaccinated, the study aims to find out whether the vaccine can prevent the symptoms of the disease from appearing in these patients. Even if symptoms appear on people who have been vaccinated, this matter can be considered a success if the vaccine prevents serious infections with Covid-19.

The study is supposed to continue until October 27, 2022, but preliminary results are expected to be released well before this date.

This announcement puts our company at the forefront of the global race to reach the anti-epidemic vaccine that has infected more than 13 million people worldwide to date, and has caused more than 570,000 deaths.

The clinical trial is supervised by the National Institutes of Health the vaccine research center, led by infectious disease expert Anthony Fuchi.

The experimental vaccine is created at lightning speed. On March 16, just two months after Chinese scientists revealed the genetic sequence of the virus, a volunteer was injected with the vaccine in Seattle. This is a record for obtaining a new vaccine, in human trials.

The federal government supports the Moderna vaccine project, with nearly half a billion dollars, and has chosen it as one of the first vaccines to engage in large-scale human trials.